HWAIF Overview

Appointment of Ian Kidson: HEALWELL AI Inc. has appointed Ian Kidson to its Board of Directors, bringing extensive experience in financial governance and healthcare leadership to support the company's mission of improving healthcare through early disease detection.

Ian Kidson's Background: Kidson has a distinguished career in both private and public sectors, having served as CFO for various companies, including Docebo Inc. and Apollo Health Corp., and held senior roles in capital markets.

HEALWELL's Mission: The company focuses on preventative care, aiming to enhance healthcare and save lives by developing advanced clinical decision support systems for early identification of diseases.

Company Overview: HEALWELL AI is publicly traded on the Toronto Stock Exchange and the OTC Exchange, and is dedicated to improving patient health outcomes through innovative technology and clinical capabilities.

Digital Health Market Growth: The global digital health market is projected to grow from USD 427.24 billion in 2025 to USD 1,500.69 billion by 2032, driven by advancements in AI and telecommunications, with North America holding a significant market share.

Aleen Inc.'s Smart Wellness Analytics: Aleen Inc. is testing a new Smart Wellness Analytics feature aimed at enhancing personal wellness awareness through AI-supported insights, focusing on user needs and privacy.

HEALWELL AI Inc. Strategic Transactions: HEALWELL AI Inc. has completed strategic transactions to streamline operations and focus on AI and software initiatives, transitioning to a pure-play digital SaaS company.

Evolent Health and AON Partnership: Evolent Health and American Oncology Network have announced a partnership to improve cancer care quality and affordability, eliminating prior authorization requirements for high-quality providers.

HEALWELL's Divestitures: HEALWELL has sold its Polyclinic Family Medicine and Specialty Clinics Group to WELL Health Clinic Network Inc. and its interest in Mutuo Health Solutions Inc. to WELLSTAR Technologies Corp., allowing HEALWELL to focus on its core AI and healthcare software business.

Joint Venture Formation: HEALWELL has established a 50/50 clinical research joint venture with WELL Health Technologies Corp., which includes Bio Pharma Services Inc. and Canadian Phase Onward Inc., aimed at advancing clinical research initiatives.

Financial Impact: The transactions are expected to streamline HEALWELL's operations, enhance its focus on high-growth areas, and strengthen its balance sheet with approximately $9.4 million in cash upon closing.

Strategic Goals: HEALWELL aims to evolve into a pure-play digital SaaS and AI business, leveraging advanced technology to improve healthcare efficiency and outcomes, while maintaining a commitment to interoperability and customer choice.

Amended Business Acquisition Report: HEALWELL AI Inc. has filed an amended and restated business acquisition report regarding its acquisition of Orion Health Holdings Limited, which closed on April 1, 2025, to update the audit report's compliance standards.

Compliance Update: The amended report reflects compliance with International Standards on Auditing (ISA) instead of ISA (New Zealand), including additional disclosures about the auditor's responsibilities as required by ISA.

Request from Ontario Securities Commission: The filing of the Amended BAR was made at the request of the Ontario Securities Commission staff during a review process.

Company Overview: HEALWELL AI is focused on preventative healthcare through artificial intelligence, aiming to enhance disease detection and improve patient health outcomes with its proprietary technology.

Business Development Roadshow: HEALWELL AI's management team engaged with prospective investors, partners, and M&A targets during a week-long business development roadshow in the UK, focusing on AI-driven preventative healthcare solutions.

Exclusive London Event: An invitation-only event in London on October 14, 2025, featured healthcare leaders and investors discussing the integration of AI in healthcare, highlighting HEALWELL's role in improving patient outcomes through advanced technologies.

Strategic Partnerships and Growth: Discussions during the roadshow emphasized collaboration opportunities within the UK healthcare ecosystem, exploring partnerships and M&A strategies to leverage HEALWELL's recent acquisition of Orion Health for international expansion.

Leadership Insights: HEALWELL's CEO and President noted the strong engagement from UK stakeholders, reinforcing the company's position as a leader in AI-driven healthcare innovation and the growing interest in technologies that enhance preventative care.

AI-Generated Real-World Data Presentation: HEALWELL, in partnership with Takeda Pharmaceutical, showcased AI-generated regulatory-grade real-world data on vedolizumab dose escalation for ulcerative colitis and Crohn's disease at the UEG Week in Berlin, demonstrating improved remission outcomes with more frequent dosing.

Unique AI Capabilities and Recognition: HEALWELL's DARWEN™ AI platform is recognized for its unique ability to generate real-world data and evidence, positioning the company as a leader in healthcare AI, and it has been named a finalist in Newsweek's AI Impact Awards 2025 for its contributions to clinical and commercial advancements.